MediWound's Q1 2026 Earnings Call: EscharEx Momentum Continues to Build
Good morning, and welcome to the MediWound first quarter 2026 earnings conference call. Yesterday, pre-market open, MediWound issued a press release announcing financial results for the first quarter ended March 31, 2026.
During the first quarter of 2026, MediWound continued to execute against its key strategic priorities, advancing EscharEx towards commercialization and expanding the global role of NexoBrid. While the timeline for EscharEx phase III VALUE study has shifted by one quarter, the underlying momentum behind the program continues to strengthen.
Ofer Gonen, Chief Executive Officer of MediWound, stated that "enrollment continues in the global phase III VALUE study in venous leg ulcers, with more than 30 sites active across the United States, Europe, and Israel." However, recruitment has progressed more gradually than originally anticipated due to operational factors. These factors include regulatory adjustments and travel requirements associated with the protocol, which have created participation challenges for older and medically complex VLU patient populations.
To support enrollment and reduce participation burden, MediWound implemented patient assistance measures, including hotel reimbursements, transportation services, and facilitated access to enhanced care. Importantly, given how quickly EscharEx works, the protocol requires daily wound assessments to determine the exact day complete debridement is achieved.
This represents a shift for measuring debridement outcomes over weeks, which may ultimately reflect one of EscharEx's key clinical and commercial advantages in real-world practice. MediWound expects the interim sample size reassessment and enrollment completion by the end of the first quarter of 2027.
At the same time, the company continues to see expanding commercial, clinical, and scientific validation supporting the broader opportunity of EscharEx across the chronic wound care market. Medline, a global leader in medical, surgical, and wound care products, has joined MediWound's collaboration network.
MediWound's collaborators now include essentially all the major advanced wound care companies relevant to the program. As part of the collaboration, Medline will provide its class-leading skin protectant, Marathon, for the upcoming DFU phase II study. This partnership further underscores the growing momentum behind EscharEx.
The company also highlighted the importance of effective, easy-to-use, and less invasive debridement approaches in chronic wound care. A peer-reviewed U.S. expert consensus document published in Wounds emphasized this need, stating that EscharEx is an innovative solution for addressing these challenges.
